Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison

被引：0
|
作者：
Reinisch, W. [1 ]
Tran, J. [2 ,3 ]
Patel, K. [4 ]
Borruel, N. [5 ]
Melmed, G. Y. [6 ]
Wegrzyn, L. [3 ]
Levy, G. [3 ]
Ilo, D. [3 ]
Gonzalez, Y. Sanchez [3 ]
Panaccione, R. [7 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Univ Washington, Comparat Hlth Outcomes Policy & Econ Inst, Seattle, WA 98195 USA
[3] AbbVie Inc, Chicago, IL USA
[4] NHS Fdn Trust, St Georges Univ Hosp, London, England
[5] Hosp Valle De Hebron, Crohns & Colitis Attent Unit, Digest Syst Serv, Barcelona, Spain
[6] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[7] Univ Calgary, Dept Gastroenterol & Hepatol, Calgary, AB, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P658
引用
收藏
页码：785 / 786
页数：2
相关论文
共 50 条
  • [1] Comparative efficacy and safety of upadacitinib vs tofacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
    An, Y-K
    Reinisch, W.
    Tran, J.
    Patel, K.
    Borruel, N.
    Melmed, Gy
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 128 - 129
  • [2] Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
    Reinisch, W.
    Panaccione, R.
    Duijvestein, M.
    Santos, D. Ceballos
    Melmed, G. Y.
    Xuan, S.
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 672 - 672
  • [3] COMPARATIVE EFFICACY AND SAFETY OF UPADACITINIB VERSUS USTEKINUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Reinisch, Walter
    Panaccione, Remo
    Duijvestein, Marjolijn
    Ceballos, Daniel
    Melmed, Gil
    Xuan, Si
    Wegrzyn, Lani R.
    Levy, Gweneth
    Ilo, Dapo
    Gonzalez, Yuri Sanchez
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S650 - S650
  • [4] Matching-Adjusted Indirect Comparison of Upadacitinib versus Vedolizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
    Reinisch, Walter
    Vermeire, Severine
    Hedin, Charlotte
    Rubin, David T.
    Panes, Julian
    Deng, Huiwen
    Xuan, Si
    Wegrzyn, Lani
    Liu, John
    Ilo, Dapo
    Zhou, Wen
    Sanchez-Gonzalez, Yuri
    Panaccione, Remo
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S520 - S521
  • [5] A MATCHING-ADJUSTED INDIRECT COMPARISON OF FILGOTINIB VERSUS TOFACITINIB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Lu, X.
    Gray, E.
    Xin, Y.
    Zhou, J.
    Jairath, V
    Lindsay, J. O.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S321 - S321
  • [6] Matching-adjusted indirect comparison of upadacitinib vs vedolizumab as induction therapy in patients with moderately to severely active ulcerative colitis
    Venugopal, K.
    Reinisch, W.
    Vermeire, S.
    Hedin, C.
    Rubin, D. T.
    Panes, J.
    Deng, H.
    Xuan, S.
    Wegrzyn, L.
    Liu, J.
    Ilo, D.
    Zhou, W.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 135 - 135
  • [7] Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn's disease: a matching-adjusted indirect comparison
    Ma, C.
    Dubinsky, M. C.
    Axelrad, J.
    Anyanwu, S.
    Tran, J.
    Lacerda, A.
    Joshi, N.
    Griffith, J.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1866 - I1867
  • [8] Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis
    Lu, Xiaoyan
    Zhou, Zheng-Yi
    Xin, Yiqiao
    Wang, Min-Jung
    Gray, Emma
    Jairath, Vipul
    Lindsay, James Oliver
    [J]. INFLAMMATORY BOWEL DISEASES, 2024, 30 (01) : 64 - 77
  • [9] Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons
    Reinisch, Walter
    Melmed, Gil Y.
    Nakase, Hiroshi
    Seidelin, Jakob
    Ma, Christopher
    Xuan, Si
    Tran, Jacinda
    Remple, Valencia
    Wegrzyn, Lani
    Levy, Gweneth
    Sanchez Gonzalez, Yuri
    Panaccione, Remo
    [J]. ADVANCES IN THERAPY, 2024, 41 (10) : 3832 - 3849
  • [10] Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitis
    Blumenstein, I.
    Xuan, S.
    Panaccione, R.
    Baert, F.
    Barreiro-de Acosta, M.
    Ye, B. D.
    Klaff, J.
    Vladea, R.
    Levy, G.
    Holweg, C. T. J.
    Gonzalez, Y. Sanchez
    Dubinsky, M. C.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : I333 - I334
12345